We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Specialized Proteins Detected In Blood of Alzheimer's Disease Patients

By LabMedica International staff writers
Posted on 28 Jun 2015
Print article
The INNO-BIA Alzbio3 multiparameter immunoassay allows the simultaneous quantification of Aß1-42, total tau, and P-tau181P in cerebrospinal fluid (CSF) using xMAP technology
The INNO-BIA Alzbio3 multiparameter immunoassay allows the simultaneous quantification of Aß1-42, total tau, and P-tau181P in cerebrospinal fluid (CSF) using xMAP technology (Photo courtesy of FUJIREBIO)
In a select group of people who later developed dementia, the levels of the lysosomal proteins were abnormal while the people still had no problems with memory or thinking skills.

These specialized brain proteins that are involved in the removal of damaged nerve cell materials may be detected in the blood of people who were diagnosed with mild cognitive impairment or dementia due to Alzheimer's disease.

Scientists at the University of California, San Francisco (CA, USA) and their colleagues took blood samples from 20 people who later developed Alzheimer's disease up to 10 years before they were diagnosed and then after they were diagnosed. Blood also was taken once from 26 people with Alzheimer's disease and 16 people with frontotemporal dementia. In addition, blood samples were taken from 46 healthy people who did not have any problems with thinking or memory skills as a control group.

Cerebrospinal fluid (CSF) levels of total tau, phosphorylated PT181-tau, and Aβ 1-42 were quantified by Luminex xMAP technology (Luminex Corporation; Austin, TX, USA) using Innogenetics INNO-BIA Alzbio3 kits (Innogenetics; Ghent, Belgium). Exosome proteins were quantified by human-specific enzyme-linked immunosorbent assays (ELISAs) for total ubiquitin (FIVEphoton Biochemicals; San Diego, CA, USA).

The investigators searched for four proteins in blood exosomes that come from lysosomes. Lysosomes act as a sort of recycling and disposal center for cells. In each case, the level of protein was significantly different for the healthy controls than for those with dementia, both before and after symptoms developed. For three of the proteins, the people with dementia had significantly higher levels; for one of the proteins, the people with dementia had significantly lower levels. For example, for many proteins with an ubiquitin "tail," or unfolded portion, the healthy controls had average levels of 200 pg/mL, while the people with Alzheimer's disease had average levels of about 375 pg/mL.

Edward J. Goetzl, MD, a professor of medicine and lead author of the study said, “These proteins are in very tiny nerve cell-derived blood particles called exosomes. Abnormal levels of the proteins may be useful biomarkers that could help us study early treatments to limit or reverse the damage to brain cells and even prevent the development of the full-blown disease. The results also show us that there are major abnormalities in how these proteins function in brain cells, which could potentially provide a new target for treatments.” The study was published on June 10, 2015, in the journal Neurology.

Related Links:

University of California San Francisco 
Luminex Corporation 
Innogenetics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.